Business plan
So far REGN is developing new dug alone or with equal partnership base (50:50). They have deal with AMGN (with additional financial support) and with P&G (with exceptional R&D support). Normally, AMGN collaboration didn't generate anything yet (so, who care), while P&G pharma business expertise can't be counted too seriously. We know that AMGN have high failure rate in picking up other bt projects and that P&G have very limited experience. This all can be seen as nothing more than neutral, if not negative for bt company.
But, my question is: “is this real true”? Only time can tell for sure.
Also, REGN have additional project, cytokine trap technology, which they develop independently. This is now ready for partnership. CEO indicate that REGN will continue to strike deal on equal level, 50:50. If this time partner is from big fat pharma (and I believe that it is), than WS will start to think differently. Or, I am lost case here and I will give-up.
Anyway, REGN business plan sound as very good one. If they progress in any of this 50:50 deal than return is there.
So, why chose REGN when there is so many *better sound* stories in Universe. Here come Yan & Com. approach. No hype, no big stories. Do your job right, do it completely. Results will come when you expect them least. This I learned from my chemistry. When I lost all my hope that I will make certain reaction/synthesis work, suddenly there is something good and new!
And, most important REGN current stock price is very attractive and chip.
Cheers,
Miljenko
|
